Lisata Therapeutics Inc.
$ 3.48
-2.79%
02 Jun - close price
- Market Cap 32,600,900 USD
- Current Price $ 3.48
- High / Low $ 3.66 / 3.42
- Stock P/E N/A
- Book Value 1.20
- EPS -1.86
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.91 %
- 52 Week High 5.07
- 52 Week Low 1.81
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
Analyst Target Price
$4.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-02-29 | 2023-11-02 | 2023-08-14 |
| Reported EPS | -0.3344 | -0.3344 | -0.49 | -0.54 | -0.55 | -0.55 | -0.59 | -0.61 | -0.65 | -0.66 | -0.65 | -0.5 |
| Estimated EPS | 0 | -0.625 | -0.59 | -0.64 | -0.53 | -0.76 | -0.77 | -0.76 | -0.72 | -0.89 | -0.93 | -0.7 |
| Surprise | -0.3344 | 0.2906 | 0.1 | 0.1 | -0.02 | 0.21 | 0.18 | 0.15 | 0.07 | 0.23 | 0.28 | 0.2 |
| Surprise Percentage | None% | 46.496% | 16.9492% | 15.625% | -3.7736% | 27.6316% | 23.3766% | 19.7368% | 9.7222% | 25.8427% | 30.1075% | 28.5714% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LSTA
2026-06-01 12:23:32
Lisata Therapeutics has disclosed preliminary communications regarding a planned tender offer by Kuva Acquisition Corp., a subsidiary of Kuva Labs Inc., in accordance with a Merger Agreement dated March 6, 2026. The tender offer has not yet commenced, and formal Schedule TO and Schedule 14D-9 materials will be filed if and when it is launched. Stockholders are advised to review these forthcoming documents for detailed information.
2026-06-01 12:08:52
Lisata Therapeutics announced that the tender offer by Kuva Labs for its outstanding shares has been delayed because Kuva Labs is reviewing its financing and negotiating with potential funding sources. The original merger agreement had its tender offer deadline extended, and there is no guarantee when, or if, the offer will commence. Lisata Therapeutics (NASDAQ:LSTA) stock has seen significant growth, and the company holds more cash than debt, which is a positive for potential acquirers.
2026-06-01 10:10:32
Lisata Therapeutics announced that Kuva Labs has delayed its planned tender offer to acquire all Lisata common stock, which was previously expected to commence on June 1, 2026. Kuva Labs is currently negotiating with financing sources and reevaluating the timing, with no guarantee that the offer will proceed. This delay introduces significant uncertainty and risk concerning the acquisition and potential returns for Lisata stockholders.
2026-06-01 10:10:32
Lisata Therapeutics announced that Kuva Labs has delayed its tender offer to acquire Lisata common stock, stating that Kuva Labs is still negotiating with financing sources. The merger agreement, initially announced in March, had its tender offer deadline amended to June 1, but there's no assurance on when or if it will commence. Lisata's stock has surged recently, likely due to merger speculation, but InvestingPro analysis indicates it is currently overvalued.
2026-06-01 10:10:32
Lisata Therapeutics announced that a prospective buyer has delayed its planned June 1 tender offer, with no assurance that the offer will proceed. The delay stems from the buyer's ongoing negotiations for financing and evaluation of timing. The company cautioned investors about the uncertainty regarding the commencement of the offer.
2026-05-29 21:10:25
Lisata Therapeutics has issued a preliminary communication regarding a planned tender offer and merger agreement with Kuva Acquisition Corp., a wholly owned subsidiary of Kuva Labs Inc., citing a merger agreement dated March 6, 2026. This filing, a Form SC TO-C, emphasizes that the tender offer has not yet commenced and is for informational purposes only, not an offer to buy or sell shares. Formal tender offer materials, including a Schedule TO and Schedule 14D-9, will be filed if and when the offer begins, which will include details on pricing and other financial terms not present in this initial disclosure.
